UK Markets closed

Auris Medical Holding AG (EARS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.0450-0.0550 (-1.77%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.1000
Open3.0800
Bid0.0000 x 800
Ask0.0000 x 900
Day's range3.0004 - 3.0900
52-week range0.7255 - 6.6000
Volume174,066
Avg. volume1,893,759
Market cap39.188M
Beta (5Y monthly)1.37
PE ratio (TTM)N/A
EPS (TTM)-1.4860
Earnings date31 Mar 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Auris Medical Announces Launch of New Corporate Website

    Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of its newly-designed corporate website www.aurismedical.com. The new website features a streamlined and modern design and also reflects the Company’s recently announced strategic repositioning. “We are proud to present our projects and products a

  • Globe Newswire

    Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2

    Bentrio™ formulation well tolerated in vitro on human nasal epitheliumUp to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controlsViral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced addit

  • Globe Newswire

    Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology

    Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission in late 2022 Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven colorectal